Interferon-beta: the neutralizing antibody (NAb) titre predicts reversion to NAb negativity

Abstract

Background: It has been reported that in some patients with MS who develop neutralizing antibodies (NAbs) against interferon beta (IFNb), antibody levels can initially increase and then decrease thereafter even when treatment is continued. Objective: To determine whether NAb titre correlates with time to reversion to NAb negativity in patients with multiple sclerosis (MS). Methods: Twenty-eight patients with MS who were NAb-positive during treatment with one of the currently available IFNbs were included in this retrospective study. NAb titres were determined by the myxovirus resistance protein A induction assay. Patients were considered NAb-positive if they had at least two consecutive samples with titres of]/20 neutralizing units (NU). Reversion to NAb-negative status was defined as two consecutive negative samples (NAb titre of B/20 NU) after NAb positivity. Results: When measured two years after treatment initiation, a NAb titre of B/75 NU had a 91.7% sensitivity and a 87.5% specificity for reversion to NAb negativity in the following two years (after a total of four years of treatment). In addition, somewhat surprisingly, patients whose serum converted to NAb-negative generally developed peak NAb titres earlier than patients who remained NAb-positive (mean time of first detection was 21 versus 38 months, respectively). Conclusion: The NAb titre might support treatment decisions in patients with MS whose test results are positive for NAbs.

Keywords

interferon beta multiple sclerosis neutralizing antibodies

Get full access to this article

View all access options for this article.

References

Wiendl H , Kieseier BC. Disease-modifying therapies in multiple sclerosis: an update on recent and ongoing trials and future strategies . Expert Opin Investig Drugs 2003; 12: 689-712 .

The IFNB Multiple Sclerosis Study Group , and the University of British Columbia MS/MRI Analysis Group . Neutralizing antibodies during treatment of multiple sclerosis with inter-feron beta-1b: experience during the first three years . Neurology 1996; 47: 889-894 .

PRISMS (Prevention of Relapses and Disability by Interferon-b-1a Subcutaneously in Multiple Sclerosis) Study Group , and the University of British Columbia MS/MRI Analysis Group . PRISMS-4: long-term efficacy of interferon-b-1a in relapsing MS . Neurology 2001; 56: 1628-1636 .

The IFNB Multiple Sclerosis Study Group . Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial . Neurology 1993; 43: 655-661 .

Bertolotto A , Malucchi S , Sala A , Orefice G , Carrieri PB , Capobianco M et al. Differential effects of three interferon betas on neutralising antibodies in patients with multiple sclerosis: a follow up study in an independent laboratory . J Neurol Neurosurg Psychiatry 2002; 73: 148-153 .

Panitch H , Goodin DS , Francis G , Chang P , Coyle PK , O’Connor P et al. for the EVIDENCE (Evidence of Interferon Dose-response: European North American Comparative Efficacy) Study Group and the University of British Columbia MS/MRI Research Group . Randomized, comparative study of interferon b-1a treatment regimens in MS. The EVIDENCE Trial . Neurology 2002; 59: 1496-1506 .

The PRISMS (Prevention of Relapses and Disability by Inter-feron-b-1a Subcutaneously in Multiple Sclerosis) Study Group . Randomised double-blind placebo-controlled study of interferon b-1a in relapsing/remitting multiple sclerosis . Lancet 1998; 352: 1498-1504 .

Rice GPA , Francis GS , and the PRISMS Study Group . Further evidence of dose effect of IFN beta-1a based on neutralizing antibody status . Poster presented at the 11th Annual Meeting of the European Neurological Society; April 21-25, 2001; Paris, France.

Clanet M , Radue EW , Kappos L , Hartung HP , Hohlfeld R , Sandberg-Wollheim M et al. and the European IFNb-1a (Avonex) Dose Comparison Study Investigators . A randomized, double-blind, dose-comparison study of weekly inter-feron b-1a in relapsing MS . Neurology 2002; 59: 1507-1517 .

10.

Cohen JA , Cutter GR , Fischer JS , Goodman AD , Heidenreich FR , Kooijmans MF et al. for the IMPACT Investigators . Benefit of interferon b-1a on MSFC progression in secondary progressive MS . Neurology 2002; 59: 679-687 .

11.

Jacobs LD , Beck RW , Simon JH , Kinkel RP , Brownscheidle CM , Murray TJ et al. and the Controlled High Risk Subjects AVONEX® Multiple Sclerosis Prevention Study (CHAMPS) Group . Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis . N Engl J Med 2000; 343: 898-904 .

12.

Herndon RM , Jacobs LD , Coats ME , Goodkin DE , Mass MK , Richert JR et al. Results of an ongoing, open-label, safety-extension study of interferon beta-1a (Avonex) treatment in multiple sclerosis . Int J MS Care Dec 1999; 2: 1-6 . Retrieved 14 December, 2002, from: http://www.mscare.com

13.

Rudick RA , Simonian NA , Alam JA , Campion M , Scaramucci JO , Jones W et al. and the Multiple Sclerosis Collaborative Research Group (MSCRG) . Incidence and significance of neutralizing antibodies to interferon beta-1a in multiple sclerosis . Neurology 1998; 50: 1266-1272 .

14.

Deisenhammer F , Reindl M , Harvey J , Gasse T , Dilitz E , Berger T. Bioavailability of interferon beta 1b in MS patients with and without neutralizing antibodies . Neurology 1999; 52: 1239-1243 .

15.

Giovannoni G , Munschauer F III , Deisenhammer F. Neutralising antibodies to interferon beta during treatment of multiple sclerosis . J Neurol Neurosurg Psychiatry 2002; 73: 465-469 .

16.

Rice GPA , Paszner B , Oger J , Lesaux J , Paty D , Ebers G. The evolution of neutralizing antibodies in multiple sclerosis patients treated with interferon b-1b . Neurology 1999; 52: 1277-1279 .

17.

Pungor E , Files JG , Gabe JD , Do LT , Foley WP , Gray JL et al. A novel bioassay for the determination of neutralizing antibodies to IFN-b1b . J Interferon Cytokine Res 1998; 18: 1025-1030 .

18.

Jilg W , Schmidt M , Deinhardt F , Zachoval R.

Hepatitis B vaccination: how long does protection last?

Lancet 1984; 2: 458-458 .

19.

Sorensen PS , Ross C , Clemmesen KM , Bendtzen K , Frederiksen JL , Jensen K et al. Clinical importance of neutralising antibodies against interferon beta in patients with relapsing-remitting multiple sclerosis . Lancet 2003; 362: 1184-1191 .

20.

Bellomi F , Scagnolari C , Tomassini V , Gasperini C , Paolillo A , Pozzilli C et al. Fate of neutralizing and binding antibodies to IFN beta in MS patients treated with IFN beta for 6 years . J Neurol Sci 2003; 215: 3-8 .

21.

Sorensen PS , Koch-Henriksen N , Ross C , Clemmesen KM , Svenson M , Bendtzen K et al. Neutralizing antibodies against interferon (IFN)-beta reduce the clinical effect in relapsing-remitting multiple sclerosis . Mult Scler 2002; 8: S8-S8 .

22.

Kreuz W , Ettingshausen CE , Auerswald G , Saguer IM , Becker S , Funk M et al. Epidemiology of inhibitors and current treatment strategies . Haematologica 2003; 88-88 : EREP04. Accessed 12 May 2004. www.haematologica.org